• InnoCan Pharma (CSE:INNO) has begun commercially producing its Derma CBD product line in Portugal
  • The first product currently being manufactured is the company’s Relief & Go CBD spray
  • InnoCan’s Spray provides temporary relief for muscle and joint pain, before and after physical activity
  • The company expects to ship samples and products to other countries within two weeks’ time
  • InnoCan Pharma (INNO) remains unchanged and is trading at C$0.17 per share

InnoCan Pharma (CSE:INNO) has begun commercially producing its Derma CBD product line in Portugal.

The company is starting with the manufacture of its Relief & Go CBD Spray, one of InnoCan’s flagship products.

The spray, which is currently Patent Pending, provides short-term relief for joint and muscle pain. Users can apply it before or after strenuous physical activity, namely sports.

The company’s Chief Technology Officer, Nir Avram, developed the Relief & Go CBD Spray himself.

“The patent pending unique formulation of Relief & Go CBD Spray contains CBD isolate as an anti-inflammatory, magnesium as a muscle relaxant, and menthol and camphor as analgesics to provide temporary relief of muscle and joint pain, before and after sports activity. 

“I believe this is an effective product which will be very successful in the market,” he said.

Other offerings from the Derma CBD product line are likely to follow in short order.

InnoCan Pharma’s CEO, Iris Bincovich, welcomed the news that production has started.

“The commencement of the production of our Derma CBD line is a significant milestone on the way to transforming from our company from a Research and Development company to commercial revenue generating enterprise. 

“We expect to ship samples and products within two weeks to countries like the UK, Germany, France, and the US, among others. The anticipated revenues from our Derma Cosmetic Premium brands, Relieve & Go, and Shir Beauty & Science, will result in revenue in the near future,” she said.

InnoCan Pharma (INNO) remains unchanged and is trading at C$0.17 at 1:47pm EDT.

More From The Market Online

Buzz on the Bullboards: The challenges amid inflation and geopolitical tensions

Canadian and U.S. stock markets grappled with a host of challenges, from surging inflation data to escalating tensions in the Middle East

Xebra Brands receives second CBD approval by Mexican authority

Xebra Brands (CSE:XBRA) announces it has received its second COFEPRIS approval for CBD product authorization in Mexico.
Canopy Growth - CEO, David Klein.

Canopy Growth shareholders approve Canopy USA asset strategy

After rearranging its capital structure, Canopy Growth (TSX:WEED) will be closer to establishing a U.S.-based multi-state operator.

The Market Online’s Weekly Cannabis Report – April 12, 2024

Canada’s cannabis stock market fluctuated this week thanks to a combination of industry-specific developments and broader market trends